Helena Melezínková

1.3k total citations · 1 hit paper
9 papers, 1.0k citations indexed

About

Helena Melezínková is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Helena Melezínková has authored 9 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 3 papers in Surgery. Recurrent topics in Helena Melezínková's work include Colorectal Cancer Treatments and Studies (4 papers), Gastric Cancer Management and Outcomes (3 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). Helena Melezínková is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Gastric Cancer Management and Outcomes (3 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). Helena Melezínková collaborates with scholars based in United States, Germany and Chile. Helena Melezínková's co-authors include Markus Moehler, G. Bodoky, Florian Lordick, Pamela Salman, Yoon‐Koo Kang, G. Kurteva, Constantin Volovăț, Vladimir Moiseyenko, Sang Cheul Oh and Akira Sawaki and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and The American Journal of Cardiology.

In The Last Decade

Helena Melezínková

9 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

2013 621 citations Florian Lordick, Yoon‐Koo Kang et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helena Melezínková United States	7	624	623	266	193	192	9	1.0k
G. Kurteva United States	10	678 1.1×	686 1.1×	254 1.0×	199 1.0×	180 0.9×	26	1.0k
Elena Elimova Canada	21	710 1.1×	529 0.8×	534 2.0×	180 0.9×	364 1.9×	119	1.4k
Ana De Juan Spain	11	567 0.9×	449 0.7×	237 0.9×	311 1.6×	269 1.4×	32	1.0k
Madeleine Hewish United Kingdom	8	340 0.5×	393 0.6×	217 0.8×	111 0.6×	267 1.4×	20	854
Haruyoshi Tanaka Japan	20	314 0.5×	352 0.6×	248 0.9×	75 0.4×	496 2.6×	52	947
Guanghai Dai China	13	354 0.6×	359 0.6×	183 0.7×	125 0.6×	168 0.9×	34	670
Henry Xiong United States	11	303 0.5×	769 1.2×	239 0.9×	32 0.2×	342 1.8×	20	1.1k
Woo Sun Kwon South Korea	16	271 0.4×	401 0.6×	89 0.3×	48 0.2×	267 1.4×	51	677
Claudia Sandomenico Italy	18	366 0.6×	562 0.9×	95 0.4×	36 0.2×	404 2.1×	52	987

Countries citing papers authored by Helena Melezínková

Since Specialization

Citations

This map shows the geographic impact of Helena Melezínková's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helena Melezínková with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helena Melezínková more than expected).

Fields of papers citing papers by Helena Melezínková

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helena Melezínková. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helena Melezínková. The network helps show where Helena Melezínková may publish in the future.

Co-authorship network of co-authors of Helena Melezínková

This figure shows the co-authorship network connecting the top 25 collaborators of Helena Melezínková. A scholar is included among the top collaborators of Helena Melezínková based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helena Melezínková. Helena Melezínková is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Baselga, José, Patricia Gómez, Richard Greil, et al.. (2013). Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology. 31(20). 2586–2592. 298 indexed citations

Lordick, Florian, Yoon‐Koo Kang, Hyun Cheol Chung, et al.. (2013). Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. The Lancet Oncology. 14(6). 490–499. 621 indexed citations breakdown →

Lordick, Florian, Yoon‐Koo Kang, Pamela Salman, et al.. (2013). Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.. Journal of Clinical Oncology. 31(15_suppl). 4021–4021. 27 indexed citations

Lordick, Florian, G. Bodoky, G. Kurteva, et al.. (2012). Cetuximab in Combination with Capecitabine and Cisplatin as First-Line Treatment in Advanced Gastric Cancer: Randomized Controlled Phase III Expand Study. Annals of Oncology. 23. ixe11–ixe11. 9 indexed citations

Reiter, Edward O., Nelly Mauras, Bindu Kulshreshtha, et al.. (2010). Bicalutamide plus Anastrozole for the Treatment of Gonadotropin-Independent Precocious Puberty in Boys with Testotoxicosis: A Phase II, Open-Label Pilot Study (BATT). Journal of Pediatric Endocrinology and Metabolism. 23(10). 999–1009. 36 indexed citations

Stein, Evan A., John Amerena, Christie M. Ballantyne, et al.. (2007). Long-Term Efficacy and Safety of Rosuvastatin 40 mg in Patients With Severe Hypercholesterolemia. The American Journal of Cardiology. 100(9). 1387–1396. 25 indexed citations

Stein, Evan A., A. David Marais, Jean Ducobu, et al.. (2007). Comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia. Journal of clinical lipidology. 1(4). 287–299. 7 indexed citations

Stein, Evan A., Helena Melezínková, Florence Le Maulf, & Alex Gold. (2005). W16-O-003 Efficacy and safety of rosuvastatin 40 MG in patients with severe type IIA and IIB hypercholesterolaemia. Atherosclerosis Supplements. 6(1). 99–100. 3 indexed citations

Veselý, Pavel, et al.. (1989). Spontaneously metastasizing rat sarcomas LW13K2 and RPS: assessment by the immunogenetic test of malignancy, in vitro behaviour and karyology.. PubMed. 35(1). 1–12. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact